Gilead Sciences duty to innovate litigation
The developments in this story so far, most recent first.
-
Milestone
California Supreme Court rules for Gilead in 'duty to innovate' case
-
· date approximate Background
A state appeals court ruling suggested Gilead could be held liable for its duty to innovate.
Approximately two years before the California Supreme Court's decision, a state appeals court issued a ruling suggesting that Gilead Sciences could be held liable for its duty to innovate. This development occurred amid thousands of patient arguments that the company was negligent for slow-walking the development of an HIV medicine that was safer than an existing drug being sold by the company.
The pharmaceutical industry expressed alarm following that ruling, amid fears that drug development decisions could be influenced by the threat of legal liability.